Purposeful is a biotech company, integrating AI and human expertise to accelerate the development of rare disease treatments.

George Drakakis

CEO

George is the CEO of Purposeful. He loves solving problems, especially when there is a clear impact in the life sciences. George has worked in the area of Cheminformatics since 2011. During his PhD at the University of Cambridge, he worked on applied modelling and mechanism of action elucidation in small molecules. After almost four years of postdoctoral research in the fields of chemo- and nanoinformatics, he decided that it was time to put this experience to the test, by co-founding Purposeful.

https://www.linkedin.com/in/drakakis/

Charalampos Chomenidis

CTO

Charalampos is co-founder and CTO of Purposeful. He has industry experience on many modern programming languages, frameworks and database systems, and is actively involved on cutting edge software technologies, from AI and IoT to Blockchain systems. His greatest passion is good software design, and always advocates the use of design patterns and best practices in coding and software architecture. He has also worked as a research associate in the field of Applied Machine Learning, with several publications under his belt. When not coding or designing software, Charalampos plays the double bass in a Jazz Trio, or records tracks in his personal studio.

https://www.linkedin.com/in/hampos/

Georgia Tsiliki

COO

Georgia is the COO and a co-founder of Purposeful. She is passionate about organizing and exploring data to improve original assumptions. Her research interests lie in the area of biomedical statistical analysis, bioinformatics and chemoinformatics, ranging from theory to design and implementation. She has extensive experience on integrating omics data and chemo-related data for a better understanding of the mechanisms of action for compounds, drugs and nanomaterials. She has worked as a researcher for more than ten years and has collaborated actively with biology and medicine specialists. Georgia received her PhD in Statistics from Imperial College London.

https://www.linkedin.com/in/georgia-tsiliki-1b79791a6/

Aris Dokoumetzidis

Scientific Advisor

Aris is co-founder of Purposeful and currently has the role of Scientific Advisor in the company. He is also an Associate Professor of Pharmacometrics in the Department of Pharmacy of the University of Athens. His expertise is mathematical modelling & simulation in drug development and clinical pharmacology. In the past he has worked as a lecturer at Queen’s University Belfast and as researcher at the University of Manchester. He has had many collaborations as a consultant for the pharmaceutical industry while he has served for 5 years as a member of the Modelling and Simulation Working Party of the European Medicines Agency.

https://www.linkedin.com/in/aris-dokoumetzidis-72bb33b/

Thalia Vlachou

Biomedical Scientist

Thalia is a Biomedical Scientist at Purposeful. She has more than 10 years of experience as experimentalist in biomedical research, primarily in the field of Molecular Oncology. She studied Biology at the University of Athens, earned her MSc from King’s College London and completed her PhD at the European Institute of Oncology (IEO) in Milan. She has expertise in systems biology approaches, molecular and cell biology, cancer genomics, single-cell and single-molecule transcriptomics. She is passionate about innovation, drug discovery and bringing healthcare solutions to the people who need it the most. She strongly believes in multidisciplinary approaches and has a record of fruitful collaborations with clinicians, computational scientists and statisticians.

Christina Bachouma

Biotechnology Scientist

Christina is a Biotechnology Scientist at Purposeful. She gained her bachelor’s degree in Applied Biology and Biotechnology from the Agricultural University of Athens. Starting as an intern, she soon found her place in the team, drawn by a passion for bioinformatics and the company’s mission—repurposing drugs for rare diseases. She contributes in using computational methods to analyze biological data, identify meaningful patterns, and support drug discovery efforts, with a strong interest in data-driven research.

Orestis Giannoukos

Machine Learning Engineer

Orestis is a versatile software engineer with a bachelor’s degree in Computer Science from the National and Kapodistrian University of Athens, he tackles a wide spectrum of code-related challenges across Purposeful’s technology stack. His academic background combined with hands-on experience allows him to approach problems with both technical depth and creative solutions. When he’s not immersed in code, you’ll find him seeking out new adventures and planning his next trip.

Artemis Michail

Biomedical Scientist

Artemis is a Biomedical Scientist at Purposeful. She earned her degree in Biology and an MSc in Biological Technology from the University of Patras. Pursuing her passion for biomedical research, she completed her PhD study at the Biomedical Research Foundation of the Academy of Greece, where she focused on uncovering novel tumor-suppressive pathways in breast cancer. Artemis has an extensive background in molecular biology, oncology, neural stem cell biology, cancer genomics, and cell signaling. She is deeply driven to innovate and develop new therapeutic strategies to address unmet clinical needs. Passionate about scientific exploration and discovery, Artemis is committed to advancing drug discovery by leveraging her expertise in the pharmacological targeting of gene regulatory networks.

Lydia Ntari

Biomedical Scientist

Lydia is a Biomedical Scientist at Purposeful, with over ten years of experience in translational research, specializing in inflammatory diseases and oncology. She holds a bachelor’s degree in Biological Sciences from the University of Edinburgh (UK) and has expanded her expertise in the study of human diseases through a MSc at UCL (UK) and a PhD at the BSRC Alexander Fleming Institute in Athens, Greece. Since 2019 she has held positions as R&D Research Scientist and Project Manager in industry with a focus on preclinical research using rodent models for the in vivo efficacy evaluation of human therapeutics. Lydia believes that drug repurposing can accelerate the path to the clinic for novel effective therapeutic approaches offering relief to human patients, while minimizing the risk of severe side effects.